Mutant TP53 promotes invasion of lung cancer cells by regulating desmoglein 3.

Purpose: Targeted therapies have markedly improved the prognosis of lung cancer patients; nevertheless, challenges persist, including limited beneficiary populations and the emergence of drug resistance. This study investigates the molecular mechanisms of mutant TP53 in lung cancer, aiming to contribute to novel strategies for targeted therapy.

Methods: The TCGA database was employed to delineate the mutational landscape of TP53 in lung cancer patients.